HC Wainwright Issues Pessimistic Estimate for NRXP Earnings

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Stock analysts at HC Wainwright reduced their FY2029 earnings estimates for shares of NRx Pharmaceuticals in a research note issued on Tuesday, November 3rd. HC Wainwright analyst P. Trucchio now expects that the company will earn $0.56 per share for the year, down from their prior estimate of $0.71. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ FY2030 earnings at $0.99 EPS.

NRx Pharmaceuticals (NASDAQ:NRXP) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The business had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million.

A number of other analysts have also issued reports on the stock. BTIG Research restated a “buy” rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a research report on Monday, September 14th. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. Wolfe Research started coverage on NRx Pharmaceuticals in a research note on Thursday, October 15th. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Tuesday. Finally, Zacks Research downgraded NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 26th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.50.

NRx Pharmaceuticals Stock Performance

Shares of NRXP opened at $2.24 on Wednesday. The company has a market capitalization of $96.99 million, a price-to-earnings ratio of -4.07 and a beta of 2.11. The company’s 50 day simple moving average is $3.01 and its 200 day simple moving average is $2.96. NRx Pharmaceuticals has a 1 year low of $1.62 and a 1 year high of $5.05.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC grew its holdings in NRx Pharmaceuticals by 30.0% in the third quarter. Commonwealth Equity Services LLC now owns 590,768 shares of the company’s stock valued at $1,725,000 after purchasing an additional 136,350 shares during the period. SBI Securities Co. Ltd. increased its position in NRx Pharmaceuticals by 292.1% during the third quarter. SBI Securities Co. Ltd. now owns 20,001 shares of the company’s stock worth $58,000 after purchasing an additional 14,900 shares during the last quarter. Prime Capital Investment Advisors LLC acquired a new position in NRx Pharmaceuticals during the third quarter worth approximately $364,000. Squarepoint Ops LLC acquired a new position in NRx Pharmaceuticals during the second quarter worth approximately $54,000. Finally, Ethos Financial Group LLC raised its stake in NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after purchasing an additional 4,000 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly severe depression and suicidal ideation. The company’s research programs are designed to address conditions in which existing therapies may have limited effectiveness or delayed onset.

NRx’s lead investigational product is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for bipolar depression with acute suicidal ideation.